Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Correspondence

Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease

Authors: Ashraf Mikhail, Christopher Brown, Jennifer Ann Williams, Vinod Mathrani, Rajesh Shrivastava, Jonathan Evans, Hayleigh Isaac, Sunil Bhandari

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Anaemia is a commonly diagnosed complication among patients suffering with chronic kidney disease. If left untreated, it may affect patient quality of life. There are several causes for anaemia in this patient population. As the kidney function deteriorates, together with medications and dietary restrictions, patients may develop iron deficiency, resulting in reduction of iron supply to the bone marrow (which is the body organ responsible for the production of different blood elements). Chronic kidney disease patients may not be able to utilise their own body’s iron stores effectively and hence, many patients, particularly those receiving haemodialysis, may require additional iron treatment, usually provided by infusion.
With further weakening of kidney function, patients with chronic kidney disease may need additional treatment with a substance called erythropoietin which drives the bone marrow to produce its own blood. This substance, which is naturally produced by the kidneys, becomes relatively deficient in patients with chronic kidney disease. Any patients will eventually require treatment with erythropoietin or similar products that are given by injection.
Over the last few years, several iron and erythropoietin products have been licensed for treating anaemia in chronic kidney disease patients. In addition, several publications discussed the benefits of each treatment and possible risks associated with long term treatment. The current guidelines provide advice to health care professionals on how to screen chronic kidney disease patients for anaemia, which patients to investigate for other causes of anaemia, when and how to treat patients with different medications, how to ensure safe prescribing of treatment and how to diagnose and manage complications associated with anaemia and the drugs used for its treatment.
Literature
1.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.CrossRefPubMedPubMedCentral
2.
Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;70:2058–65.CrossRefPubMed
3.
4.
National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on chronic kidney disease in adults: assessment and management 2014. National Institute for Clinical Excellence. Available on http://​www.​nice.​org.​uk/​guidance/​cg182. Accessed 15 June 2017.
5.
Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. NephrolDialTransplant. 2004;19(Suppl 2):ii1–47.
6.
Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–59.
7.
KDOQI. National Kidney Foundation clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 Suppl 3):S16–85.
8.
KDIGO. Clinical practice guideline for Anaemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.CrossRef
9.
Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin α on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148–56.CrossRefPubMed
10.
Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of haemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46:799–811.CrossRefPubMed
11.
Oski FA, Brugnara C, Nathan DG. A diagnostic approach to the anaemic patient. In: Nathan and Oski's Haematology of infancy and childhood. 6th ed. Philadelphia: Saunders; 2003. p. 409–18.
12.
World Health Organisation. Iron deficiency anaemia, assessment, prevention and control: a guide for programme managers. 2001.
13.
Beall CM, Goldstein MC. Haemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet. Am J Phys Anthropol. 1987;73:433–8.CrossRefPubMed
14.
Cheng CK, Chan J, Cembrowski GS, van Assendelft OW. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Lab Hematol. 2004;10:42–53.CrossRefPubMed
15.
de Lusignan S, Chan T, Stevens P, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22:234–41.CrossRefPubMed
16.
Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anaemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anaemia. Blood. 2004;104:2263–8.CrossRefPubMed
17.
Ishimura E, Nishizawa Y, Okuno S, et al. Diabetes mellitus increases the severity of anaemia in non-dialyzed patients with renal failure. J Nephrol. 1998;11:83–6.PubMed
18.
Bosman DR, Winkler AS, Marsden JT, et al. Anaemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24:495–9.CrossRefPubMed
19.
Thomas MC, MacIsaac RJ, Tsalamandris C, et al. Unrecognized anaemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003;26:1164–9.CrossRefPubMed
20.
Thomas MC, MacIsaac RJ, Tsalamandris C, et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant. 2004;19:1792–7.CrossRefPubMed
21.
El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anaemia with diabetes mellitus in moderate kidney insufficiency: the kidney early evaluation program. Kidney Int. 2005;67:1483–8.CrossRefPubMed
22.
Erslev AJ, Besarab A. The rate and control of baseline red cell production in haematologically stable patients with uraemia. J Lab Clin Med. 1995;126(3):283–6.PubMed
23.
Naets JP, Garcia JF, Tousaaint C, et al. Radioimmunoassay of erythropoietin in chronic uraemia or nephric patients. Scand J Haematol. 1986;37:390–4.CrossRefPubMed
24.
Ross RP, McCrea JB, Besarab A. Erythropoietin response to blood loss in haemodialysis patients in blunted but preserved. ASAIO J. 1994;40:M880–5.CrossRefPubMed
25.
Movilli E, Pertica N, Camerini C, et al. Pre dialysis versus post dialysis haematocrit evaluation during erythropoietin therapy. Am J Kidney Dis. 2002;39:850–3.CrossRefPubMed
26.
Bellizzi V, Minutolo R, Terracciano V, et al. Influence of the cyclic variation of hydration status on haemoglobin levels in haemodialysis patients. Am J Kidney Dis. 2002;40:549–55.CrossRefPubMed
27.
Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in haemodialysis patients. Clin Nephrol. 1995;44:238–40.PubMed
28.
Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis. 1999;34:508–13.CrossRefPubMed
29.
Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Luft FC, et al. Diagnosis of iron deficiency anaemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995;26:292–9.CrossRefPubMed
30.
31.
Coban E, Timuragaoglu A, Meric M. Iron deficiency anaemia in the elderly: prevalence and endoscopic evaluation of the gastrointestinal tract in outpatients. Acta Haematol. 2003;110:25–8.CrossRefPubMed
32.
Ioannou GN, Rockey DC, Bryson CL, et al. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med. 2002;113:276–80.CrossRefPubMed
33.
Ioannou GN, Spector J, Scott K, et al. Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anaemia. Am J Med. 2002;113:281–7.CrossRefPubMed
34.
Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in haemodialysis patients. J Am Soc Nephrol. 2000;11:530–8.PubMed
35.
Besarab A, Dalton CL. Maintaining higher TSATs and other iron indices is beneficial in management of anaemic haemodialysis patients. Nephrol Nurs J. 2001;28:429–34.PubMed
36.
Coladonato JA, Frankenfield DL, Reddan DN, et al. Trends in anaemia management among US haemodialysis patients. J Am Soc Nephrol. 2002;13:1288–95.
37.
Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance haemodialysis patients. Am J Kidney Dis. 2003;42:761–73.CrossRefPubMed
38.
McClellan WM, Frankenfield DL, Wish JB, et al. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult haemodialysis patients: results from the 1998 end-stage renal disease Core indicators project. Am J Kidney Dis. 2001;37:E36.PubMed
39.
Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in haemodialysis patients. Am J Kidney Dis. 2001;38:109–17.CrossRefPubMed
40.
41.
Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in haemodialysis patients. Kidney Int. 2001;60(6):2406–11.CrossRefPubMed
42.
Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte haemoglobin content in the evaluation of iron status of haemodialysis patients. Kidney Int. 1997;52(1):217–22.CrossRefPubMed
43.
Kaneko Y, Miyazaki S, Hirasawa Y, et al. Transferrin saturation versus reticulocyte haemoglobin content for iron deficiency in Japanese haemodialysis patients. Kidney Int. 2003;63:1086–109.CrossRefPubMed
44.
Bhandari S, Turney JH, Brownjohn AM, et al. Reticulocyte indices in patients with end stage renal disease on haemodialysis. J Nephrol. 1998;11(2):78–82.PubMed
45.
Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16(7):1416–23.CrossRefPubMed
46.
Chen YC, Hung SC, Tarng DC. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in haemodialysis patients. Am J Kidney Dis. 2006;47(6):1036–44.CrossRefPubMed
47.
National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for Anaemia in chronic kidney disease. Section III. Clinical practice recommendations for anaemia in chronic kidney disease in children. Am J Kidney Dis. 2006;47:S86–108.
48.
Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anaemic patients with non-dialysis dependent CKD. Kidney Int. 2005;68:2846–56.CrossRefPubMed
49.
Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in pre-dialysis chronic renal failure patients. Ren Fail. 2002;24:307–13.CrossRefPubMed
50.
Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234–8.CrossRefPubMed
51.
Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967–74.CrossRefPubMed
52.
Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anaemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55–62.CrossRefPubMed
53.
Ahsan N. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Adv Perit Dial. 2000;16:80–4.PubMed
54.
55.
Macdougall IC, Bock AH, Carrera F, et al. For the FIND-CKD study investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075–84.CrossRefPubMedPubMedCentral
56.
Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31:646–55.CrossRefPubMed
57.
Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in haemodialysis patients. Am J Kidney Dis. 1999;34:21–8.CrossRefPubMed
58.
Macdougall IC, Chandler G, Elston O, et al. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. Am J Kidney Dis. 1999;34:S40–6.CrossRefPubMed
59.
Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–6.CrossRefPubMed
60.
Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694–9.CrossRefPubMed
61.
Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;0:1–13. 10.1093/ndt/gfv096
62.
Macdougall IC, Bircher AJ, Eckardt KU, et al. Conference participants. Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2016;89(1):28–39.CrossRefPubMed
63.
Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65(3):1091–8.CrossRefPubMed
64.
Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term haemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87–93.CrossRefPubMed
65.
Rostoker G, Griuncelli M, Loridon C, et al. Haemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125(10):991–9.CrossRefPubMed
66.
Coyne DW, Kapoian T, Suki W, et al. DRIVE study group. Ferric gluconate is highly efficacious in anaemic haemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV iron with elevated Ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18:975–84.CrossRefPubMed
67.
Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anaemia correction in incident haemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16(7):2180–9.CrossRefPubMed
68.
Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving haemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.CrossRefPubMed
69.
Singh AK, Szczech L, Tang KL, et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.CrossRefPubMed
70.
Drüeke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anaemia. N Engl J Med. 2006;355(20):2071–84.CrossRefPubMed
71.
72.
Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved haemoglobin outcomes. Kidney Int. 2008;74(6):791–8.CrossRefPubMedPubMedCentral
73.
Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anaemia treatment. Kidney Int. 2010;77(3):239–46.CrossRefPubMed
74.
KDOQI clinical practice guideline and clinical practice recommendations for anaemia in chronic kidney disease, 2007 update of haemoglobin target. Am J Kidney Dis. 2007;50(3):471–530.
75.
Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.CrossRefPubMed
76.
Macdougall IC, Tomson CR, Steenkamp M, et al. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK renal registry data incorporating 30,040 patient-years of follow-up. Nephrol Dial Transplant. 2010;25(3):914–9.CrossRefPubMed
77.
Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anaemia management practices in incident haemodialysis patients. JAMA. 2010;303(9):857–64.CrossRefPubMed
78.
Locatelli F, Aljama P, Canaud B, et al. Anaemia working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25(9):2846–50.CrossRefPubMed
79.
80.
81.
Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anaemic patients with end-stage renal disease. Results of a phase III multicentre clinical trial. Ann Intern Med. 1989;111(12):992–1000.CrossRefPubMed
82.
Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anaemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989;321(3):158–63.CrossRefPubMed
83.
Locatelli F, Olivares J, Walker R. Et al; European/ Australian NESP 980202 study group. Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency. Kidney Int. 2001;60(2):741–7.CrossRefPubMed
84.
Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving haemodialysis. Department of Veterans Affairs Cooperative Study Group on erythropoietin in Haemodialysis patients. N Engl J Med. 1998;339(9):578–83.CrossRefPubMed
85.
Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin α at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 2003;18:362–9.CrossRefPubMed
86.
Vanrenterghem Y, Bárány P, Mann JF, et al. European/ Australian NESP 970200 study group. Randomized trial of darbepoetin alfa for treatment of renal anaemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62(6):2167–75.CrossRefPubMed
87.
Spinowitz B, Coyne DW, Lok CE, et al. RUBRA study investigators: C.E.R.A. Maintains stable control of haemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008;28(2):280–9.CrossRefPubMed
88.
Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by haemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007;50(6):989–1000.CrossRefPubMed
89.
Tolman C, Richardson D, Bartlett C, et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol. 2005;16:1463–70.CrossRefPubMed
90.
Jadoul M, Vanrenterghem Y, Foret M, et al. Darbepoetin α administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004;19:898–903.CrossRefPubMed
91.
Fishbane S, Berns JS. Haemoglobin cycling in haemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–43.CrossRefPubMed
92.
Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anaemia in haemodialysis patients. Am J Kidney Dis. 2002;40(1):110–8.5.CrossRefPubMed
93.
94.
Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23–33.CrossRefPubMed
95.
Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for haemoglobin-survival paradox in haemodialysis. Am J Kidney Dis. 2008;52:727–36.CrossRefPubMedPubMedCentral
96.
97.
Rizzo JD, Brouwers M, Hurley P, et al. American Society of Haematology and the American Society of Clinical Oncology practice guideline update committee. American Society of Haematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–59.CrossRefPubMed
98.
99.
NKF-K/DOQI clinical practice guidelines for Anaemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37:S182–238.
100.
Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in haemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691–701.CrossRefPubMedPubMedCentral
101.
Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:77–83.CrossRefPubMedPubMedCentral
102.
Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–6.CrossRefPubMedPubMedCentral
103.
Novey HS, Pahl M, Haydik I, et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72:224–8.PubMed
104.
Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279–89.CrossRefPubMed
105.
Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243:1726–31.CrossRefPubMed
106.
Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in haemodialysis patients. Am J Kidney Dis. 1996;28:529–34.CrossRefPubMed
107.
Michael B, Coyne DW, Fishbane S, et al. Ferrlecit publication committee. Sodium ferric gluconate complex in haemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61(5):1830–9.CrossRefPubMed
108.
109.
Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003;64:572–8.CrossRefPubMed
110.
Nairz M, Schroll A, Sonnweber T, Weiss G, et al. The struggle for iron - a metal at the host-pathogen interface. Cell Microbiol. 2010;12:1691–702.CrossRefPubMed
111.
112.
Fritsche G, Nairz M, Werner ER, et al. Nramp1-functionality increases iNOS expression via repression of IL-10 formation. Eur J Immunol. 2008;38:3060–7.CrossRefPubMed
113.
114.
Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant. 2014;29:809–22.CrossRefPubMedPubMedCentral
115.
Ishida JH, Johansen KL. Iron and infection in haemodialysis patients. Semin Dial. 2014;27(1):26–36.CrossRefPubMed
116.
Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in haemodialysis patients. J Am Soc Nephrol. 2013;24(7):1151–8.CrossRefPubMedPubMedCentral
117.
Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86(4):845–54.CrossRefPubMed
118.
Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in haemodialysis patients. J Am Soc Nephrol. 2002;13(3):734–44.PubMed
119.
Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among haemodialysis patients. J Am Soc Nephrol. 2004;15(6):1623–32.CrossRefPubMed
120.
Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in haemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070–80.CrossRefPubMed
121.
Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in haemodialysis patients. PLoS One. 2013;8(11):e78930.CrossRefPubMedPubMedCentral
122.
Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicentre prospective study of risk factors for bacteraemia in chronic haemodialysis patients. J Am Soc Nephrol. 1998;9:869–76.PubMed
123.
Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteraemia in chronic haemodialysis patients. Clin Nephrol. 2002;57(6):457–61.CrossRefPubMed
124.
Horl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant. 2000;15(Suppl 4):43–50.CrossRefPubMed
125.
Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant. 1998;13(Suppl 2):3–8.CrossRefPubMed
126.
Jacobs C, Horl WH, Macdougall IC, et al. European best practice guidelines 5: target haemoglobin. Nephrol Dial Transplant. 2000;15(Suppl 4):15–9.CrossRefPubMed
127.
Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol. 1975;30:411.CrossRefPubMed
128.
Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346.CrossRefPubMed
129.
Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol. 2004;15:2728.CrossRefPubMed
130.
Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469.CrossRefPubMed
131.
Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol. 2004;15:398.CrossRefPubMed
132.
Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant. 2003;18:865.CrossRefPubMed
133.
Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381.CrossRefPubMed
134.
Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2008;3:193.CrossRefPubMed
135.
Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389.CrossRefPubMed
136.
Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re- treatment: multiple options. Nephrol Dial Transplant. 2005;20(Suppl 4):iv23.CrossRefPubMed
137.
Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the research on adverse drug events and reports (RADAR) project. Blood. 2005;106:3343.CrossRefPubMedPubMedCentral
138.
Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363(9423):1768–71.CrossRefPubMed
139.
140.
Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292(13):1555–62.CrossRefPubMed
141.
142.
Soosay A, O'Neill D, Counihan A, et al. Causes of sensitisation in patients awaiting renal transplantation in Ireland. Ir Med J. 2003;96(4):109–12.PubMed
143.
House AA, Pham B, Pagé DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant. 1998;13(7):1763–9.CrossRefPubMed
144.
Popovsky MA, Ransil BJ. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematology. 1996;12(1):1–3.PubMed
145.
Manchester Kidney Transplant, NWKTA Audit Project; 2003.
146.
147.
148.
Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anaemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant. 2002;2(5):429–35.CrossRefPubMed
149.
Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of post-transplant anaemia in paediatric and young adult renal transplant recipients. Am J Kidney Dis. 2002;40(6):1306–18.CrossRefPubMed
150.
Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anaemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3(7):835–45.CrossRefPubMed
151.
Abraham KA, Little MA, Dorman AM, et al. Haemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int. 2000;13(6):443–7.CrossRefPubMed
152.
Epstein M, Landsberg D. Cyclosporine-induced thrombotic microangiopathy resulting in renal allograft loss and its successful reuse: a report of two cases. Am J Kidney Dis. 1991;17(3):346–8.CrossRefPubMed
153.
Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000;36(4):844–50.CrossRefPubMed
154.
Trimarchi HM, Truong LD, Brennan S, et al. Report of two cases and review of the literature. Transplantation. 1999;67(4):539–44.CrossRefPubMed
155.
Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55(6):2457–66.CrossRefPubMed
156.
Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transplant. 1994;9(8):1191–3.CrossRefPubMed
157.
Morris-Stiff G, Evans M, Baboolal K, et al. Haemolytic uraemic syndrome associated with OKT3. Transpl Int. 1996;9(5):522–3.CrossRefPubMed
158.
MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271–80.CrossRefPubMed
159.
Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc. 2003;35(3 Suppl):25S–34S.CrossRefPubMed
160.
Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4(12):2001–6.CrossRefPubMed
161.
Crew RJ, Radhakrishnan J, Cohen DJ, et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant. 2005;20(1):203–9.CrossRefPubMed
162.
Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anaemia in kidney transplant recipients. J Am Soc Nephrol. 2004;15(5):1347–52.CrossRefPubMed
163.
Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis. 2001;38(3):510–7.CrossRefPubMed
164.
Naito M, Kawashima A, Akiba T, Takanashi M, et al. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic haemodialysis patients. Am J Nephrol. 2003;23(5):287–93.CrossRefPubMed
165.
So BJ, Chae KM, Lee KK, et al. Pure red cell aplasia due to parvovirus B19 infection in a renal transplant patient: a case report. Transplant Proc. 2000;32(7):1954–6.CrossRefPubMed
166.
Vales-Albertos LJ, García-Cárdenas M, Chávez-Becerra S, et al. Pure red cell aplasia associated with parvovirus B19 infection in renal transplantation: the first case report in Mexico. Transplantation. 2005;79(6):739.CrossRefPubMed
167.
Debska-Slizień A, Chamienia A, Król E, et al. Haemolytic anaemia after renal transplantation: analysis of case reports. Transplant Proc. 2003;35(6):2233–7.CrossRefPubMed
168.
Peces R, Díaz Corte C, Navascués RA. Haemolytic anaemia caused by graft-versus host reaction in ABO-non identical renal transplants from blood group O donors. Nefrologia. 2001;21(4):395–401.PubMed
169.
Li FK, Chan TM, Lai KN. Alloimmune haemolysis after renal transplantation. Am J Nephrol. 2000;20(6):473–5.CrossRefPubMed
170.
Moulin B, Ollier J, George F. Serum erythropoietin and reticulocyte maturity index after renal transplantation: a prospective longitudinal study. Nephron. 1995;69(3):259–66.CrossRefPubMed
171.
Schmidt R, Kupin W, Dumler F, et al. Influence of the pre-transplant hematocrit level on early graft function in primary cadaveric renal transplantation. Transplantation. 1993;55(5):1034–40.CrossRefPubMed
172.
Vasquez EM, Pollack R. Effect of pre-transplant erythropoietin therapy on renal allograft outcome. Transplantation. 1996;62(7):1026–8.CrossRefPubMed
173.
Paganini EP, Braun WE, Latham D, et al. Renal transplantation: results in haemodialysis patients previously treated with recombinant human erythropoietin. ASAIO Trans. 1989;35(3):535–8.CrossRefPubMed
174.
Lee DB. Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation. Am J Kidney Dis. 1991;18(4 Suppl 1):54–6.PubMed
175.
Van Loo A, Vanholder R, Bernaert P, et al. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transplant. 1996;11(9):1815–21.CrossRefPubMed
176.
Van Biesen W, Vanholder R, Veys N, et al. Efficacy of erythropoietin administration in the treatment of anaemia immediately after renal transplantation. Transplantation. 2005;79(3):367–8.CrossRefPubMed
177.
Jindal KK, Hirsch DJ, Belitsky P, et al. Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure. Nephrol Dial Transplant. 1992;7(2):143–6.CrossRefPubMed
178.
Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anaemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol. 1994;5(5):1216–22.PubMed
179.
Becker BN, Becker YT, Leverson GE, Heisey DM. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant. 2002;17(9):1667–73.CrossRefPubMed
180.
Choukroun G, Kamar N, Dussol B, et al. For the CAPRIT study investigators. Correction of post kidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23(2):360–8.CrossRefPubMedPubMedCentral
181.
Traindl O, Barnas U, Franz M, et al. Recombinant human erythropoietin in renal transplant recipients with renal anaemia. Clin Transpl. 1994;8(1):45–8.
182.
Yoshimura N, Oka T, Ohmori Y, Aikawa I. Effects of recombinant human erythropoietin on the anaemia of renal transplant recipients with chronic rejection. Transplantation. 1989;48(3):527–9.CrossRefPubMed
Metadata
Title
Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Authors
Ashraf Mikhail
Christopher Brown
Jennifer Ann Williams
Vinod Mathrani
Rajesh Shrivastava
Jonathan Evans
Hayleigh Isaac
Sunil Bhandari
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0688-1

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue

Research article

Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients

Case report

Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy – case report and literature review

Case report

Case report - atypical hemolytic uremic syndrome triggered by influenza B

Research article

Person-centred care in chronic kidney disease: a cross-sectional study of patients’ desires for self-management support

Research article

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Research article

Renal replacement therapy in acute kidney injury from a Chinese cross-sectional study: patient, clinical, socioeconomic and health service predictors of treatment

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits